Chronic Pain in Parkinson's Disease: Prevalence, Sex Differences, Regional Anatomy, and Multiple Comorbidities

Natalia S. Ogonowski[1,2], Freddy Chafota[1], Fangyuan Cao[1,2], Amanda Wei Yin Lim[1,2,3],
Victor Flores-Ocampo[1,2], Santiago Díaz-Torres[1,2], Zuriel Ceja[1,2], Luis M. García-Marín[1,2],
Scott F. Farrell[4] , Kishore R. Kumar[5,6,7,8], Jane Alty[9,10,11], George D. Mellick[12], Trung Thành Ngô[4]
and Miguel E. Renteria[1,2,13,*]

1. Brain & Mental Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
2. School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.
3. Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
4. RECOVER Injury Research Centre; NHMRC Centre of Research Excellence: Better Health Outcomes for Compensable Injury; STARS Education and Research Alliance; The University of Queensland and Surgical, Treatment & Rehabilitation Service (STARS), Metro North Health, Herston, Brisbane QLD 4029, Australia.
5. Department of Neurology and Molecular Medicine Laboratory, Concord Repatriation General Hospital, Concord, NSW 2139, Australia.
6. Sydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.
7. Translational Neurogenomics Group, Genomics and Inherited Disease Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
8. School of Clinical Medicine, UNSW Medicine & Health, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney
9. Wicking Dementia Research and Education Centre, University of Tasmania, Liverpool Street, Hobart, TAS 7001, Australia
10. School of Medicine, University of Tasmania, Hobart, TAS 7001, Australia
11. Royal Hobart Hospital, Hobart, TAS 7001, Australia
12. Griffith Institute for Biomedicine and Glycomics, Griffith University, QLD 4111, Australia
13. School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia

* **Correspondence:** Miguel E. Renteria, PhD; Brain & Mental Health Program, QIMR Berghofer Medical Research Institute, Locked Bag 2000, Royal Brisbane Hospital, Herston QLD 4029, Australia. Email: Miguel.Renteria@qimrberghofer.edu.au

ABSTRACT

Chronic pain (pain on most days or daily for ≥3 months) is prevalent among people living with Parkinson's disease (PD). We analysed data from 10,631 Australian individuals with PD to assess the prevalence, severity, anatomical distribution, clinical history, and associated factors. Two-thirds (66.2%) reported chronic pain, with females experiencing higher prevalence (70.8%) and severity (4.7 vs. 4.3 on a 10-point scale). Common pain sites included the buttocks (35.6%), lower back (25.4%), neck (19.4%), and knees (17.2%). Chronic pain was strongly linked to comorbid depression, sleep disorders, and osteoarthritis (p < 0.05). Environmental exposures such as pesticides, heavy metals, and alcohol were associated with higher pain prevalence, especially in males (p < 0.05). These findings emphasise the substantial burden of chronic pain in PD, highlighting sex differences and strong links to multimorbidity. Further research is warranted to clarify sex-specific treatments and identify novel therapeutic targets.

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by a range of motor and non-motor symptoms. In recent decades, the significance of non-motor symptoms in PD has increasingly drawn the attention of both clinicians and researchers[1,2]. In particular, chronic pain is one of the most prevalent, affecting between 30%–85% of individuals with PD [3,4]. Despite its high prevalence and substantial impact on patients' quality of life, chronic pain in PD remains underdiagnosed and poorly managed in clinical settings[5].

The pathophysiology of chronic pain in PD remains poorly understood but is thought to involve both peripheral and central mechanisms. Pain can emerge at any stage of the disease and may even precede the onset of motor symptoms, highlighting its significance in PD progression. Despite its prevalence, chronic pain in PD remains one of the least understood aspects of the disease, largely due to its heterogeneous presentation and the inherent challenge in measuring subjective experiences of pain[5]. Pain in PD encompasses several types, including musculoskeletal, neuropathic, dystonic, central nociceptive, neuropathic, and nociplastic pain classifications[6]. These types also often overlap, further complicating diagnosis and treatment [7].

Specific demographic and clinical factors have been associated with the variability of chronic pain in PD. Age at onset[8], sex[9–11], ethnicity, and the presence of comorbid conditions can all shape the perception and experience of pain[10–12]. For example, females with PD may experience more severe or more frequent pain than males[10]. At the same time, people with younger-onset PD may report different pain patterns compared to those diagnosed later in life[13]. These observations highlight a critical gap in understanding how these factors interact to influence chronic pain in PD, thus emphasising the need for further investigation.

Here, we analysed data from 10,631 participants from a nationwide cohort of Australian adults living with PD to (i) determine the prevalence of chronic pain, (ii) examine age and sex differences associated with chronic pain, (iii) assess the severity and anatomical distribution of chronic pain among individuals with PD, and (iv) identify social and lifestyle factors linked to chronic pain variability. Together, these objectives aim to elucidate the relationship between chronic pain and PD as the foundation for further targeted studies into optimal diagnostic and therapeutic intervention approaches.

RESULTS

Prevalence of chronic pain in PD

Among the 10,631 participants in the cohort, 7,036 (66.2%) reported experiencing chronic pain, with a significantly higher prevalence among females (70.8%, 2,782/3,930) compared to males (63.5%, 4,254/6,701, p<0.05).

At enrollment, the mean age of participants was 70.9 years (± 9.1), with an average age of PD symptom onset at 63.9 years (± 10.6), followed by formal PD diagnosis at 65.6 years (± 9.9) and initiation of levodopa treatment at 66.1 years (± 10.2). Participants with chronic pain were, on average, younger than those without chronic pain (70.3 ± 9.2 vs. 72.3 ± 9.0, p < 0.05), and they experienced symptom onset and began levodopa treatment at younger ages (Table 1). Age patterns were similar across both sexes, regardless of chronic pain status.

Participants reporting chronic pain also had a higher weight and BMI compared to those without chronic pain. Also, a significant height difference was noted, with individuals experiencing chronic pain being slightly shorter on average. This trend was consistent across male and female participants (Table 1).

Educational attainment was also analysed by gender. Among males, 6,668 out of 6,701 participants provided education data, with 26.7% (1,781/6,668) having completed secondary education and 26.1% (1,742/6,668) having pursued vocational education and training (VET). Similarly, among females, the highest proportions had completed secondary education (31.3%, 1,225/3,914) and VET (24.3%, 950/3,914) (Table 1).

Chronic Pain as an Index Symptom

Chronic pain was reported as the initial non-motor symptom in approximately 1.28% (106/8,305) of participants, with a prevalence of 1.3% (69/5,312) in males and 1.24% (37/2,993) in females. The most common initial symptom was fine tremors or shaking, reported in 52.2% (4,330/8,305) cases, followed by motor features in 16.8% (1,398/8,305) participants. Other early symptoms included rigidity or stiff joints (8.7%, 724/8,305), loss of smell (6.6%, 550/8,305), and restless legs (4.8%, 401/8,305). Dysgraphia and loss of balance were also noted as initial symptoms in the participants, 2.2% (181/8,305) and 1.4% (115/8,305), respectively. In addition, 6% (500/8,305) of participants reported a variety of other initial symptoms, such as falls, anxiety, speech impairments, fatigue, weakness, constipation, depression, and sleep disturbances.

Chronic Pain Severity

Among the 7,036 participants reporting chronic pain, the average pain severity score was 4.4 ± 2.2 out of 10, with discomfort reported on both sides of the body. Females reported higher mean pain scores than males (4.7 ± 2.2 vs. 4.3 ± 2.2, $p < 0.05$) (Figure 1).

Anatomical Distribution of Chronic Pain

Figure 2 illustrates the distribution of pain across 66 specific body regions, as indicated by participants. Among males, the most commonly reported areas were the buttocks (right: 35.6%, left: 32.6%), lower back (right: 24.5%, left: 22.2%), back of the neck (right: 14.1%, left: 14.5%), and front of the knees (right: 14.2%, left: 13.5%). A similar pattern was observed among females, with the buttocks (right: 34.0%, left: 31.8%) being the most frequently reported region, followed by the lower back (right: 25.4%, left: 22.6%), back of the neck (right: 19.4%, left: 19.0%), and front of the knees (right: 17.2%, left: 16.1%). Additionally, 10–15% of female participants reported pain in the front of the feet, upper legs, upper back, and the front and back of the shoulders. Overall, females reported significantly higher levels of pain across all anatomical regions compared to males ($p < 0.05$) (see Supplementary Material, S2). A *Poisson* regression analysis revealed that high pain severity scores were associated with an increase in the counts of anatomical body regions ($p < 0.05$). Additionally, being a male was associated with a slight decrease in the number of body sites reported ($p = 0.007$) compared to females.

Other Reported Forms of Chronic Pain

Among the 7,036 participants with chronic pain, 6,911 reported experiencing multiple forms of pain. Of these, 51.5% (3,557/6,911) reported pain associated with motor symptoms, while 49.5% (3,422/6,911) experienced joint pain. Additionally, 19.9% (1,374/6,911) reported sensations of pins and needles, while 18.1% (1,253/6,911) described burning sensations in their hands. Other reported pain types included general body aches that were difficult to characterise, pain linked to involuntary small muscle movements, pain during 'off' periods, and pain associated with large muscle jerks, which affected 16.6% to 15.2% (1,148–1,051/6,911) of participants. Less common symptoms included discomfort in the mouth while chewing or speaking, sensitivity to light touch, and internal organ pain (e.g., stomach, liver, kidneys, bowels) reported by 9.3% to 2.1% (641–145/6,911) of participants. Females also reported significantly higher levels across nine different forms of pain compared to males ($p < 0.05$) (Table 2).

Medical Comorbidities with Chronic Pain

Significant differences were observed in the prevalence of certain comorbid conditions between patients with and without chronic pain. Those with chronic pain were more likely to report having sleep apnoea, depression, osteoarthritis, mild cognitive impairment, osteoporosis, inflammatory bowel disease, rheumatoid arthritis, essential tremor, hypothyroidism, high blood pressure, REM sleep behaviour disorder, and restless legs syndrome (p<0.05). In contrast, no significant association was identified between chronic pain and conditions such as psoriasis, stroke, or peptic ulcer (p>0.05) (Table 3).

Lifestyle Factors in Chronic Pain

We identified significant associations between chronic pain and self-reported exposure to pesticides, herbicides, and heavy metals among cohort participants. Individuals with chronic pain reported higher consumption of alcohol and caffeinated soft drinks (p<0.05) while smoking or having quit smoking was slightly less common in this group (p<0.05). We found no significant differences in coffee or tea consumption between participants with and without chronic pain.

Sex differences were also observed in males with chronic pain who reported a higher prevalence of pesticide/herbicide exposure, alcohol intake, and caffeinated soft drink consumption compared to females (p<0.05). Conversely, tea consumption was significantly higher among females with chronic pain compared to their male counterparts (p<0.05). No significant sex differences were observed in smoking behaviours or exposure to heavy metals. These findings underscore the association of various lifestyle factors with chronic pain in PD patients, with notable variations across sex groups (Table 4).

Risk Factors Associated with Chronic Pain

Univariate and multivariate logistic regression analyses revealed several significant risk factors associated with chronic pain, as shown in Table 5. Gender was significantly associated with a higher likelihood of chronic pain in both univariate (OR = 1.39, 95% CI = 1.28–1.52) and multivariate analyses (OR = 1.48, 95% CI = 1.33–1.63, p < 0.001). The risk of chronic pain decreased by 11% for every 5-year increase in age (multivariate OR = 0.89, 95% CI = 0.87–0.92, p < 0.001). Higher BMI, depression, REM sleep behaviour disorder, and pesticide exposure were also independently associated with increased odds of chronic pain in the multivariate model (p < 0.001). Depression exhibited the strongest association, with an adjusted OR of 1.70 (95% CI = 1.52–1.90). Factors such as heavy metal poisoning, sleep apnea, essential tremor, caffeinated soft drink consumption, and alcohol use showed significant associations in univariate analyses but were not retained in the final multivariate model.

DISCUSSION

The current study is the largest investigation of chronic pain in people living with PD. It provides evidence of the prevalence, severity, and anatomical distribution of chronic pain in PD and its relationship with sociodemographic variables, medical comorbidities, and lifestyle factors. The results suggest chronic pain is highly prevalent in PD—affecting 66.2% of participants—with approximately 1.28% experiencing it as an initial symptom. Females with PD reported higher rates of, and more severe, chronic pain compared to males. In both sex groups, the most often reported body areas were the buttocks, lower back, back of the neck, and front of the knee.

Participants reported experiencing various forms of chronic pain, such as joint and motor-related problems. In addition, there was a significant association between chronic pain and several medical comorbidities, such as depression (33.2%), sleep apnoea (17.1%), and restless legs syndrome (15.8%). We also observed a correlation between chronic pain and environmental/lifestyle factors such as smoking, alcohol and caffeine intake, and heavy metal and pesticide exposure, with a significantly higher exposure rate in males.

The prevalence of chronic pain in the current study was 66.2%, consistent with previous reports ranging between 30–85%. This wide variation highlights the heterogeneous nature of chronic pain in PD, with likely influences from geographical and cultural contexts. For instance, 90% of 100 Russian individuals with PD had reported experiencing discomfort[14] compared with 83% of the 413 participants in a Norwegian study[15]. Several cross-sectional studies conducted in Mexico, Japan, the UK, Italy, France, Turkey, and Germany also revealed a high prevalence of pain. In Mexico, for example, 88.6% of 341 participants with PD reported chronic pain[16], whereas studies from Japan[17] and the UK reported prevalence rates of 78.6% (n = 324) and between 62.6%–76% (n = 100–123)[18,19], respectively. About 70% of 402 Italian PD participants have reported experiencing pain[20], followed by studies of PD individuals in France[21], Turkey[11], and Germany[22] reporting 67% (n = 450), 64% (n = 167), and 61% (n = 181) with persistent pain lasting longer than three months (respectively). Moderate prevalence rates were also found in India[12] (52.1%, n = 114) and Brazil[10] (56%, n = 50). The discrepancies in chronic pain prevalence across these studies may be due to methodological differences, variations in the definition of chronic pain in PD, the number of cases studied, and population characteristics.

To provide context, Miller et al.[23] and the nationwide report *The Cost of Pain in Australia*[24] estimate the prevalence of chronic pain in individuals aged 70 to be 23% among males and 30% among females. Thus, the prevalence observed in this study (66.2%) is markedly higher than that reported for the general population.

Chronic pain as an initial symptom of PD has been reported from other cohorts, suggesting that pain is part of the early manifestations of PD. Gatto et al., for example, showed a higher association between a genetic variant in the *LRRK* gene (G2019S) and pain as the first symptom in an Argentinian cohort[25]. Similarly, Guiffrida et al. found that approximately one-quarter of participants reported experiencing pain in the early phases of the disease[26]. In the current study, about 1.28% of PD participants experienced chronic pain as an initial symptom with heterogeneity of PD pain types in terms of their gender, location, origin, and age[27]. Consistent with previous studies, we found that the intensity of chronic pain reported in females was higher compared to males[19,28]. The median pain severity score was 4.7 for females and 4.3 for males (with a combined median score of 4.4). While statistically significant, these differences may be too small to be clinically meaningful.

Contrary to our findings, a Swedish cohort study reported that the median pain score did not differ between genders[29]. However, female participants reported experiencing higher intensity forms of pain than male participants, including pain associated with motor complications in PD, such as discomfort during the "off" period and involuntary muscle and joint movements, as well as scorching sensation in the hands and feet. In addition, they also presented with indiscernible body aches, various internal organ-related pains, sensitivity to light touch, and discomfort in the mouth when eating. Notably, this discomfort was present on both sides of the body. Consistent with these findings, a recent study revealed that females with bilateral PD carrying the rs2283265 polymorphism located in the dopamine receptor 2 gene (*DRD2*) are at a higher risk of PD-related pain[30]. Furthermore, the *CHRNA4* gene rs1044397 polymorphism may influence the age of PD onset in females with chronic pain rather than affecting the disease's progression or severity[31].

Our multivariate analysis corroborated these findings, with gender being a strong determinant of chronic pain, with women exhibiting nearly a 50% higher likelihood of experiencing chronic pain compared to males. This aligns with evidence suggesting that gender differences in pain sensory processing and responses to pain relief may also be influenced by variations in sex chromosomes and hormonal variables such as testosterone and oestradiol, pointing to a genetic and physiological predisposition for PD-related pain in females. Interestingly, we also found that younger age was associated with a higher likelihood of reporting chronic pain, which contrasts with other studies

suggesting increased pain prevalence in older adults. A possible explanation could be that older patients may develop pain tolerance or underreport pain due to psychosocial factors, such as age-related stoicism or the normalisation of pain as part of aging. In contrast, younger individuals may experience more intense pain due to factors such as greater motor dysfunction, neuroplasticity, and increased psychosocial stress related to the impact of the disease on their daily lives[32].

On the other hand, socioeconomic factors such as educational attainment and income have emerged as notable socio-demographic variables that may intersect with the prevalence and management of chronic pain[33,34], including in PD. In our cohort, secondary education and vocational education and training (VET) were the predominant levels of educational attainment among both genders. However, undergraduate and postgraduate educational attainment was greater in individuals without chronic pain compared to those with chronic pain. The relationship between education and health outcomes, including chronic pain, warrants closer scrutiny, as higher educational attainment may be a proxy for higher socioeconomic status, potentially enhanced health literacy and access to healthcare resources, influencing the capacity to manage chronic conditions. Conversely, lower levels of education may exacerbate socioeconomic vulnerabilities, such as reduced access to adequate pain management strategies[33], and negative health behaviours (e.g., smoking).

Previous studies have indicated that the affected body parts in PD participants vary between females and males of different ancestries, making it difficult to draw an accurate pain topography. Regardless of the number of pain locations, pain in the buttocks was the most prevalent in both males and females (~35–31% of cases), followed by the lower back (~25–22%), front of the knee (~17–13%) and back of the neck (~19–14%), with females reporting more pain in those regions than males. According to the Australian Institute of Health & Welfare (AIHW) 2023 statistics, the prevalence of back pain in Australia is 16%[35]. While structural changes in the lumbar spine, such as spinal canal stenosis, radiculopathy from arthritis, bony spurs, cumulative compression fractures, and disc herniation, may contribute to back pain, may contribute to symptoms[36], psychosocial factors, including stress and mental health, are recognised as stronger predictors of back pain outcomes[37]. In PD patients, chronic musculoskeletal pain (as defined by the IASP ICD-11 classification) is often exacerbated by symptoms such as dystonia, rigidity, and postural instability, which compound spinal issues[38]. Furthermore, PD has been associated with decreased pain thresholds, reduced pain tolerance, and inhibition of the substantia gelatinosa's pain suppression pathways[39,40]. These mechanisms are broadly consistent with nociplastic pain, which is characterised by altered central pain processing without clear evidence of tissue damage or structural pathology[41].

Truncal instability, a common feature of PD, may further contribute to chronic pain originating from the back and neck[42,43]. Participants in that study reported chronic pain in an average of four to five anatomical regions, indicating widespread and diverse experiences of pain. Higher pain severity scores were also associated with an increase in the number of body sites affected. Although the current study's questionnaire did not specifically interrogate the underlying mechanisms of pain (e.g., neuropathic/nociplastic/nociceptive pathways), our results provide valuable clues. For instance, joint-related pain may indicate nociceptive/musculoskeletal mechanisms; burning or pins-and-needles sensations could suggest neuropathic pain[44]; and widespread pain associated with depression or hyperalgesia is consistent with nocicplastic pain[41].

Gender differences in chronic pain experiences may further reflect underlying biological and psychosocial factors. Females have been shown to exhibit hormonal fluctuations, variations in endogenous opioid system responses, and heightened susceptibility to psychosocial stressors, all of which may amplify pain perception and severity[18,45]. These observations highlight the need for personalised, multidisciplinary approaches to pain management in PD.

The prevalence, severity, and types of chronic pain can vary depending on the stage of the disease and individual factors such as medical comorbidities. The comorbidity burden increases as PD progresses, underscoring the necessity of ongoing clinical assessment and management[46]. The current study identified significant associations between chronic pain and multiple comorbidities. Although a direct causal relationship between them has not been firmly established, their interaction may exacerbate pain perception through several potential mechanisms[47,48]. For instance, 33.2% of PD participants experiencing chronic pain have been reported as suffering from depression. This finding is consistent with their well-documented bidirectional relationship, suggesting that depression may act as an additional risk factor for chronic pain in PD[49].

Conversely, depression can alter the perception of PD-related pain and accelerate its progression to a severe and refractory state[50]. In the current study, sleep disorders also emerged as notable comorbidities, with 11%–17% of PD participants reporting REM sleep behaviour disorder and sleep apnoea. Chronic pain can negatively impact sleep quality, leading to sleep fragmentation and insomnia. Poor sleep also lowers pain thresholds and increases pain sensitivity, creating a vicious cycle that further aggravates both conditions[51,52]. Musculoskeletal conditions such as osteoarthritis and osteoporosis are common comorbidities among PD patients. In the current cohort, 4% of participants reported osteoporosis as a comorbidity, a condition that contributes to musculoskeletal

pain experienced by 40%–75% of individuals with PD. This pain is frequently associated with truncal deformities and bone mineralisation disorders such as osteoporosis[53].

Furthermore, 10% of participants in the current cohort reported comorbid osteoarthritis—a condition linked to specific pain characteristics, including an increased likelihood of experiencing paresthesia and akathisia-related pain[54]. Other comorbidities observed in PD participants with chronic pain included rheumatoid arthritis and inflammatory bowel disease, which may exacerbate PD-related pain by increasing inflammatory mechanisms. In addition, restless leg syndrome, essential tremor, and mild cognitive impairment, which are associated with dopamine deficiency and disrupted brain circuitry, can further exacerbate the experience of pain in PD. For example, changes in nociceptive processing and regulation have been observed in early PD, which may be related to the same dopaminergic dysfunction that causes tremors. The basal ganglia, which are involved in the generation of Parkinsonian tremors, also play a role in pain processing, suggesting that these patients experience more severe symptoms[55,56].

PD participants reporting chronic pain in our cohort exhibited higher rates of alcohol consumption, coffee and tea drinking, smoking, and exposure to pesticides, herbicides, and heavy metals, which is consistent with the existing literature[34]. Smoking and alcohol use have long been linked to pain in both epidemiological and clinical data and implicated in the etiology of multiple conditions contributing to chronic pain. Several toxic substances introduced by cigarette smoking can damage the interior lining of blood vessels and impair their oxygen-carrying capacity, leading to tissue malnutrition, degeneration, and death[57,58]. Smoking may also accelerate degenerative processes and induce structural changes across multiple systems[58]. Studies suggest that prolonged exposure to nicotine can disrupt the processing of nociceptive inputs[58,59], which is an observed abnormality in PD individuals with pain complaints[60,61]. Furthermore, the systemic inflammatory effect of smoking may contribute to an increased risk of chronic pain[62].

Similarly, alcohol exerts a direct neurotoxic effect on both central and peripheral nerves, leading to harmful changes in neural structures and musculoskeletal systems, while its excessive consumption has been linked to various chronic pain conditions and poorer pain outcomes in terms of onset and severity. However, evidence regarding the relationship between alcohol intake and chronic pain is less consistent and often suggests a curvilinear association[63]. Furthermore, there is a complex interplay between alcohol and cigarette smoking in people with chronic pain—the impacts are potentially bidirectional, in which individuals may be motivated to drink and smoke as coping mechanisms to alleviate or avoid pain and its accompanying discomfort[57,58,64]. Pesticide and

herbicide exposure and heavy metal poisoning are known risk factors for PD owing to their neurotoxic properties. These toxic substances can induce oxidative stress, neuroinflammation, mitochondrial dysfunction, and dopaminergic neuronal cell death[65–67], all of which contribute to the development of PD. In line with previous reports indicating adverse and long-term health impacts across a wide spectrum[65,68], our study further suggests a link between these factors and a higher prevalence of chronic pain in PD.

Our multivariate analysis highlighted specific factors with robust associations with chronic pain risk, including higher BMI, depression, REM sleep behaviour disorder, and pesticide exposure. However, variables such as heavy metal poisoning and lifestyle behaviours like smoking and alcohol consumption were significant in univariate analyses but not retained in the multivariate model. This suggests their effects may be mediated or confounded by other factors. Thus, it is important to consider both direct and indirect influences when evaluating chronic pain risk in PD and to emphasise the need for targeted interventions addressing modifiable risk factors.

We acknowledge several limitations in the current study that should be considered when interpreting the results. First, self-selection bias may be introduced by the recruitment method, and the use of a patient-reported questionnaire is subject to recall bias. In addition, patients with advanced forms of the disease, including cognitive impairment and severe musculoskeletal disabilities, were less likely to participate. Furthermore, our study did not include a control group of individuals without PD. However, previous studies have shown that pain is prevalent in the non-PD population, which allows for indirect comparisons between pain in PD and non-PD groups.[69] Another limitation is that participants were required to be on antiparkinsonian medications to be eligible for inclusion in the study, which means that our findings may not fully reflect the pain experiences of non-medicated PD patients. To address this issue, future studies should include participants with different medication treatment profiles to capture a broader spectrum of pain experiences in PD. We also could not distinguish between primary PD-related pain and non-PD chronic pain, as our data did not include detailed information to enable classifying the origin of participants' pain. As such, both types of pain were grouped in our analyses, which may potentially confound the interpretation of the results. Lastly, the lack of explicit information about the types of pain and pain treatments limits the accurate assessment of chronic pain characteristics in our cohort. The use of antiparkinsonian medications and their effects on pain have yet to be reported. Furthermore, differences in sample size, demographic characteristics, and methodological approaches across cohorts could also contribute to inconsistencies when comparing studies with

other populations. These factors highlight the necessity for more rigorous and uniform methods in assessing chronic pain in PD to ensure the comparability of results across studies.

In conclusion, our study provides compelling evidence that chronic pain is a complex and highly prevalent feature of Parkinson's disease, affecting roughly two-thirds of individuals and often co-occurring with comorbidities and environmental risk factors. Younger participants and females reported more frequent and severe pain, while anatomical distribution patterns and diverse pain types highlight the complexity of pain phenotypes in PD. These findings emphasise the urgent need for improved clinical recognition, comprehensive assessment, and tailored management strategies that integrate medical, psychosocial, and lifestyle interventions. Importantly, they also stress the value of considering modifiable risk factors, such as mental health conditions and environmental exposures, in shaping targeted prevention and therapeutic approaches. Future research should aim to clarify the underlying mechanisms driving chronic pain variability in PD and develop evidence-based guidelines to enhance patient quality of life and treatment outcomes.

METHODS

Study design and participants

The Australian Parkinson's Genetics Study (APGS) is an ongoing nationwide cohort study that aims to characterise the clinical, genetic, and phenotypic diversity of PD in Australia. The target recruitment is 20,000 participants, including 10,000 diagnosed with PD and 10,000 neurologically healthy controls without a positive family history of PD.

Recruitment was undertaken through a combination of assisted mailouts sent to Australian residents who have been prescribed medications with an indication for PD in the last five calendar years and a public outreach campaign leveraging traditional and social media channels. Participation entails completing an online questionnaire, which includes sections on living with PD, personal clinical history (with a specific focus on chronic pain), family history of neurological conditions, lifestyle, and environmental risk factors. The online survey is hosted on the Qualtrics platform, but participants without computer access or those preferring a paper format can request a traditional paper version. The recruitment strategy of APGS has been detailed elsewhere [70].

We included participants who met the following criteria: **(i)** residency in Australia at the time of participation; **(ii)** any age; **(iii)** a diagnosis of PD with prescribed medications for PD; and **(iv)**

completion of the pain section in the questionnaire. Participants were excluded if they had not completed at least 80% of the questionnaire or did not provide details regarding pain. A full list of questionnaire items included in this analysis is provided in *Supplementary Material 1*. As of the analysis time (October 2024), 10,631 eligible participants had completed the questionnaire. Chronic pain was defined as pain persisting for more than three months and occurring on most days or daily.

All participants provided written informed consent, and the information follows the Commonwealth Privacy Act (1988) and National Health and Medical Research Council (NHMRC) Guidelines. The QIMR Berghofer Human Research Ethics Committee granted this study's ethical approval under project number P3711.

Study Questionnaire

The baseline questionnaire collected information on **(i)** sociodemographic variables (e.g., age, ethnicity, height, weight, highest qualifications, sex); **(ii)** PD-related variables, including age at PD diagnosis, initial PD symptoms and experiences with memory changes, falls, sleep issues, and other related conditions; **(iii)** pain-related variables including subjective scoring of chronic pain severity on a scale from 0–10 (with 10 representing the most severe pain) on average, identification of specific body sites affected by pain using a body map, and other forms of pain experiences; and **(iv)** presence of 15 medical comorbidities along with lifestyle factors such as smoking, alcohol consumption, and exposure to pesticides or herbicides (see *Supplementary Material, S1*).

Statistical Analysis

Data analyses were performed using R version 4.3.2 on a MacOS Sonoma 14.4.1 platform. This study investigated the relationship between chronic pain in PD across a range of variables, including sociodemographic and PD-related variables, medical comorbidities, and lifestyle factors. Descriptive statistics were reported as proportions, percentages, frequency distributions, and measures of central tendency. Correlation analyses were conducted using Pearson's correlation coefficient for continuous variables. Bivariate relationships were assessed using Chi-squared and Fisher's exact tests for categorical variables, as well as independent samples t-tests for continuous variables. Statistical significance was defined as $p < 0.05$.

We conducted multiple logistic regression analyses using a backward stepwise approach to identify factors associated with chronic pain. The baseline multivariate model included all variables with a $p < 0.20$. Multicollinearity among explanatory variables was assessed using the variance inflation factor (VIF). Variables were retained in the model if they had a $p < 0.05$ and improved the model's

fit. The linearity of continuous variables was evaluated using multivariate fractional polynomial models and their plots. Missing data were addressed by restricting analyses to participants with complete data for all explanatory variables included in the model. Model fit was assessed using the Hosmer-Lemeshow goodness-of-fit test, while classification tables and the area under the receiver operating characteristic (ROC) curve were used to evaluate predictive performance. Results were reported as odds ratios (OR) with 95% confidence intervals (CI) for each risk factor associated with chronic pain.

Data availability

The data supporting the findings of this study are not publicly accessible due to participant privacy considerations. However, anonymised datasets can be made available to qualified researchers upon request to the corresponding author. Data sharing will be contingent upon obtaining all necessary ethical approvals and signing an institutional data transfer agreement.

Code availability

Researchers may contact the corresponding author to request access to the code used for data processing and analysis.

REFERENCES

1. Winkler, J. *et al.* Parkinson's disease risk score: moving to a premotor diagnosis. *J. Neurol.* **258**, S311–5 (2011).

2. Santos-García, D. & de la Fuente-Fernández, R. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease. *J. Neurol. Sci.* **332**, 136–140 (2013).

3. Falup-Pecurariu, C., Fanciulli, A., Borgohain, R., Ray Chaudhuri, K. & Metta, V. *New Insights in Non-Motor Symptoms in Parkinson's Disease*. (Frontiers Media SA, 2024).

4. Gálvez-Jiménez, N., Korczyn, A. D. & Lugo-Sanchez, R. *Non-Motor Parkinson's Disease*. (Cambridge University Press, 2022).

5. Ford, B. Pain in Parkinson's disease. *Mov. Disord.* **25 Suppl 1**, S98–103 (2010).

6. Nardelli, D. *et al.* Pain in Parkinson's disease: a neuroanatomy-based approach. *Brain Commun* **6**, fcae210 (2024).

7. Marques, A. & Brefel-Courbon, C. Chronic pain in Parkinson's disease: Clinical and pathophysiological aspects. *Rev. Neurol.* **177**, 394–399 (2021).

8. Buhmann, C., Kassubek, J. & Jost, W. H. Management of pain in Parkinson's disease. *J. Parkinsons. Dis.* **10**, S37–S48 (2020).

9. Defazio, G., Tinazzi, M. & Berardelli, A. How pain arises in Parkinson's disease? *Eur. J. Neurol.* **20**, 1517–1523 (2013).

10. Gao, L., Yang, Y., Cai, L. & Xiong, Y. Gender Differences in Pain Subtypes among Patients with Parkinson's Disease. *J. Integr. Neurosci.* **21**, 120 (2022).

11. Zella, M. A. S. *et al.* Landscape of pain in Parkinson's disease: impact of gender differences. *Neurol. Res.* **41**, 87–97 (2019).

12. Tai, Y.-C. & Lin, C.-H. An overview of pain in Parkinson's disease. *Clin Park Relat Disord* **2**, 1–8 (2020).

13. Mehanna, R. & Jankovic, J. Young-onset Parkinson's disease: Its unique features and their impact on quality of life. *Parkinsonism Relat. Disord.* **65**, 39–48 (2019).

14. Winter, Y. *et al.* Social and clinical determinants of quality of life in Parkinson's disease in a Russian cohort study. *Parkinsonism Relat. Disord.* **16**, 243–248 (2010).

15. Beiske, A. G., Loge, J. H., Rønningen, A. & Svensson, E. Pain in Parkinson's disease: Prevalence and characteristics. *Pain* **141**, 173–177 (2009).

16. Mostofi, A., Morgante, F., Edwards, M. J., Brown, P. & Pereira, E. A. C. Pain in Parkinson's disease and the role of the subthalamic nucleus. *Brain* **144**, 1342–1350 (2021).

17. Kubo, S.-I. *et al.* A Japanese multicenter survey characterizing pain in Parkinson's disease. *J. Neurol. Sci.* **365**, 162–166 (2016).

18. Valkovic, P. *et al.* Pain in Parkinson's Disease: A Cross-Sectional Study of Its Prevalence, Types, and Relationship to Depression and Quality of Life. *PLoS One* **10**, e0136541 (2015).

19. Rodríguez-Violante, M. *et al.* Clinical Determinants of Parkinson's Disease-associated Pain Using the King's Parkinson's Disease Pain Scale. *Mov Disord Clin Pract* **4**, 545–551 (2017).

20. Defazio, G. *et al.* Pain as a Nonmotor Symptom of Parkinson Disease: Evidence From a Case-Control Study. *Arch. Neurol.* **65**, 1191–1194 (2008).

21. Nègre-Pagès, L. *et al.* Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. *Mov. Disord.* **23**, 1361–1369 (2008).

22. Buhmann, C. *et al.* Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. *J. Neurol.* **264**, 758–769 (2017).

23. Miller, A., Sanderson, K., Bruno, R., Breslin, M. & Neil, A. The prevalence of pain and analgesia use in the Australian population: Findings from the 2011 to 2012 Australian National Health Survey. *Pharmacoepidemiology and Drug Safety* (2017) doi:10.1002/pds.4301.

24. Stories, P. The cost of pain in Australia. *Deloitte* https://www.deloitte.com/au/en/services/economics/analysis/cost-pain-australia.html.

25. Gatto, E. M. *et al.* The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics. *Neurosci. Lett.* **537**, 1–5 (2013).

26. Giuffrida, R., Vingerhoets, F. J. G., Bogousslavsky, J. & Ghika, J. Pain in Parkinson's disease. *Rev. Neurol.* **161**, 407–418 (2005).

27. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. *Lancet Neurol.* **8**, 464–474 (2009).

28. Behari, M., Srivastava, A., Achtani, R., Nandal, N. & Dutta, R. B. Pain Assessment in Indian Parkinson's Disease Patients Using King's Parkinson's Disease Pain Scale. *Ann. Indian Acad. Neurol.*

23, 774–780 (2020).

29. Skogar, O. *et al.* Parkinson's disease patients' subjective descriptions of characteristics of chronic pain, sleeping patterns and health-related quality of life. *Neuropsychiatr. Dis. Treat.* **8**, 435–442 (2012).

30. Eryilmaz, I. E. *et al.* Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson's disease. *Clin. Neurol. Neurosurg.* **199**, 106257 (2020).

31. Zhang, L. M., Zhang, X. P., Chen, Y. Q. & Ye, W. Association of CHRNA4 gene rs1044396 and rs1044397 polymorphisms with Parkinson's disease symptoms and smoking. *Genet. Mol. Res.* **14**, 5112–5122 (2015).

32. Domenichiello, A. F. & Ramsden, C. E. The silent epidemic of chronic pain in older adults. *Progress in neuro-psychopharmacology & biological psychiatry* **93**, 284 (2019).

33. Farrell, S. F. *et al.* C-Reactive Protein (CRP) is Associated With Chronic Pain Independently of Biopsychosocial Factors. *The journal of pain* **25**, (2024).

34. Farrell, S. F. *et al.* A Shared Genetic Signature for Common Chronic Pain Conditions and its Impact on Biopsychosocial Traits. *J Pain* **24**, 369–386 (2023).

35. Back problems. *Australian Institute of Health and Welfare* https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/back-problems.

36. Knezevic, N. N., Candido, K. D., Vlaeyen, J. W. S., Van Zundert, J. & Cohen, S. P. Low back pain. *Lancet* **398**, 78–92 (2021).

37. O'Keeffe, M., George, S. Z., O'Sullivan, P. B. & O'Sullivan, K. Psychosocial factors in low back pain: letting go of our misconceptions can help management. *Br J Sports Med* **53**, 793–794 (2019).

38. Perrot, S. *et al.* The IASP classification of chronic pain for ICD-11: chronic secondary musculoskeletal pain. *Pain* **160**, 77–82 (2019).

39. Magrinelli, F. *et al.* Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. *Parkinsons Dis.* **2016**, 9832839 (2016).

40. Skidmore, F. M. *et al.* The emerging postural instability phenotype in idiopathic Parkinson disease. *NPJ Parkinsons Dis* **8**, 28 (2022).

41. Kosek, E. *et al.* Chronic nociplastic pain affecting the musculoskeletal system: clinical criteria and grading system. *Pain* **162**, 2629–2634 (2021).

42. Palakurthi, B. & Burugupally, S. P. Postural Instability in Parkinson's Disease: A Review. *Brain Sci* **9**,

(2019).

43. Forsyth, A. L. *et al.* Flexed Truncal Posture in Parkinson Disease: Measurement Reliability and Relationship With Physical and Cognitive Impairments, Mobility, and Balance. *J. Neurol. Phys. Ther.* **41**, 107–113 (2017).

44. Finnerup, N. B. *et al.* Neuropathic pain: an updated grading system for research and clinical practice. *Pain* **157**, 1599–1606 (2016).

45. Aging and Disease: The Epigenetic Bridge. in *Epigenetics in Human Disease* 935–973 (Academic Press, 2018).

46. Minar, M., Dragasek, J. & Valkovic, P. Comorbidities in Parkinson's disease – The results from national epidemiological study cosmos. *J. Neurol. Sci.* **405**, 211 (2019).

47. Santiago, J. A., Bottero, V. & Potashkin, J. A. Biological and Clinical Implications of Comorbidities in Parkinson's Disease. *Front. Aging Neurosci.* **9**, 394 (2017).

48. Burchill, E. *et al.* The impact of psychiatric comorbidity on Parkinson's disease outcomes: a systematic review and meta-analysis. *Lancet Reg Health Eur* **39**, 100870 (2024).

49. Prange, S., Klinger, H., Laurencin, C., Danaila, T. & Thobois, S. Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment. *Drugs Aging* **39**, 417–439 (2022).

50. Sheng, J., Liu, S., Wang, Y., Cui, R. & Zhang, X. The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. *Neural Plast.* **2017**, 9724371 (2017).

51. Hunt, J. *et al.* Sleep and circadian rhythms in Parkinson's disease and preclinical models. *Mol. Neurodegener.* **17**, 2 (2022).

52. Klyne, D. M. *et al.* Poor sleep versus exercise: A duel to decide whether pain resolves or persists after injury. *Brain, behavior, & immunity - health* **35**, (2023).

53. Choi, S.-M. *et al.* The Association of Musculoskeletal Pain with Bone Mineral Density in Patients with Parkinson's Disease. *Eur. Neurol.* **77**, 123–129 (2017).

54. Rana, A. Q. *et al.* Osteoarthritis Increases Paresthestic and Akathisic Pain, Anxiety Case-ness, and Depression Severity in Patients With Parkinson's Disease. *Front. Neurol.* **9**, 409 (2018).

55. Paul, D. A., Qureshi, A. R., Jamal, M. K. & Rana, A. Q. Cross-sectional design: Link between Parkinson's pain and Restless Leg Syndrome. *J. Geriatr. Psychiatry Neurol.* **35**, 622–626 (2022).

56. Ondo, W. G., Vuong, K. D. & Jankovic, J. Exploring the relationship between Parkinson disease and restless legs syndrome. *Arch. Neurol.* **59**, 421–424 (2002).

57. Ditre, J. W., Brandon, T. H., Zale, E. L. & Meagher, M. M. Pain, nicotine, and smoking: research findings and mechanistic considerations. *Psychol. Bull.* **137**, 1065–1093 (2011).

58. Shi, Y., Weingarten, T. N., Mantilla, C. B., Hooten, W. M. & Warner, D. O. Smoking and pain: pathophysiology and clinical implications. *Anesthesiology* **113**, 977–992 (2010).

59. Galeote, L., Kieffer, B. L., Maldonado, R. & Berrendero, F. Mu-opioid receptors are involved in the tolerance to nicotine antinociception. *J. Neurochem.* **97**, 416–423 (2006).

60. Schestatsky, P. *et al.* Neurophysiologic study of central pain in patients with Parkinson disease. *Neurology* **69**, 2162–2169 (2007).

61. Cattaneo, C. & Jost, W. H. Pain in Parkinson's Disease: Pathophysiology, Classification and Treatment. *J. Integr. Neurosci.* **22**, 132 (2023).

62. Klyne, D. M., Barbe, M. F., James, G. & Hodges, P. W. Does the Interaction between Local and Systemic Inflammation Provide a Link from Psychology and Lifestyle to Tissue Health in Musculoskeletal Conditions? *Int J Mol Sci* **22**, (2021).

63. Karimi, R., Mallah, N., Nedjat, S., Beasley, M. J. & Takkouche, B. Association between alcohol consumption and chronic pain: a systematic review and meta-analysis. *Br. J. Anaesth.* **129**, 355–365 (2022).

64. Zale, E. L., Maisto, S. A. & Ditre, J. W. Interrelations between pain and alcohol: An integrative review. *Clin. Psychol. Rev.* **37**, 57–71 (2015).

65. Shah, R. Pesticides and Human Health. in *Emerging Contaminants* (IntechOpen, 2021).

66. Pyatha, S., Kim, H., Lee, D. & Kim, K. Association between Heavy Metal Exposure and Parkinson's Disease: A Review of the Mechanisms Related to Oxidative Stress. *Antioxid. Redox Signal.* **11**, 2467 (2022).

67. Hong, S., Hwang, J., Kim, J. Y., Shin, K. S. & Kang, S. J. Heptachlor induced nigral dopaminergic neuronal loss and Parkinsonism-like movement deficits in mice. *Exp. Mol. Med.* **46**, e80 (2014).

68. Hu, R. *et al.* Long- and Short-Term Health Effects of Pesticide Exposure: A Cohort Study from China. *PLoS One* **10**, e0128766 (2015).

69. Mills, S. E. E., Nicolson, K. P. & Smith, B. H. Chronic pain: a review of its epidemiology and

associated factors in population-based studies. *BJA: British Journal of Anaesthesia* **123**, e273 (2019).

70. Bivol, S. *et al.* Australian Parkinson's Genetics Study (APGS): pilot (n=1532). *BMJ Open* **12**, e052032 (2022).

Acknowledgments

We are deeply grateful to all the participants of the Australian Parkinson's Genetics Study (APGS) whose invaluable contributions and commitment made this research possible. APGS is supported by the Shake It Up Australia Foundation and the Michael J. Fox Foundation for Parkinson's Research (MJFF-021952). MER thanks the support from the Rebecca L. Cooper Medical Research Foundation (F20231230). LMGM is supported by a UQ Research Training Scholarship from the University of Queensland (UQ). KRK is supported by grants from the Medical Research Future Fund and the Ainsworth 4 Foundation (unrelated to the current study). JA is supported by grants from the National Health & Medical Research Foundation (unrelated to the current study).

Author information

NSO, FCh, and MER conceived the study. NSO and FCao curated the data. NSO conducted the statistical analyses under the direction and supervision of MER. NSO and FCh prepared the initial draft and incorporated feedback from all co-authors. MER designed the cohort study, oversaw participant recruitment and data collection for APGS, and obtained funding for the study. TTN designed the pain module for genetic and epidemiological investigations as part of a broader Precision Pain Medicine R&D program. All authors contributed to data interpretation, critically reviewed each draft of the report, and approved the final submitted version.

Declaration of interests

JA has received honoraria from AbbVie and Stada for delivering medical lectures; financial support from AbbVie, Novo Nordisk, and GP2 to attend medical conferences; honoraria for editorial work with *npj Parkinson's disease*; and royalties from CRC Press for medical textbooks. These activities are not related to the work presented in this paper.

All authors declare no conflicts of interest.

Figure 1. **Chronic pain severity**. This histogram illustrates the distribution of chronic pain severity scores (0–10) reported by participants in the cohort who experienced persistent pain (n = 7,036). The x-axis denotes pain severity scores, and the y-axis shows the number of participants reporting each value. Males are indicated by blue bars and females by red bars, enabling comparison of pain severity distributions between genders.

Figure 2. **Anatomical distribution of chronic pain**. This figure shows the anatomical distribution of chronic pain based on participant self-reports. The body maps, presented in both front and back views, are divided into 66 distinct regions on both the right (R) and left (L) sides. Each region is colour-coded according to the percentage of participants who reported experiencing pain in that area, with the following intervals: 50–35%, 35–25%, 25–15%, 15–5%, and 5–0%.

Table 1. Demographic characteristics of study participants

Variables	All	PD with chronic pain	PD without chronic pain
Total (n, %)	10631	7036 (66.2)	3595 (33.8)
Age (mean [SD])	70.9 ± 9.1	70.3 ± 9.2	72.3 ± 9 *
Age at onset (mean [SD])	63.9 ± 10.6	62.9 ± 10.8	66.1 ± 10.2 *
Age of PD diagnosis (mean [SD])	65.6 ± 9.9	64.1 ± 9.1	66.6 ± 9.0*
Age of treatment with levodopa (mean [SD])	66.1 ± 10.2	65.0 ± 10.2	68.1 ± 9.7 *
BMI (kg/m2)	27.2 ± 5.4	27.6 ± 5.6	26.2 ± 4.8 *

Variables	All Male	PD with chronic pain	PD without chronic pain
Total (n, %)	6701 (63)	4254 (63.5)	2447 (36.5)
Age (mean [SD])	71.2 ± 9.1	70.5 ± 9.1	72.4 ± 8.9 *
Age at onset (mean [SD])	64.3 ± 10.6	63.2 ± 10.7	66.3 ± 10.1 *
Age of PD diagnosis (mean [SD])	65.6 ± 9.8	64.2 ± 9.9	67.1 ± 9.1*
Age of treatment with levodopa (mean [SD])	66.3 ± 10.1	65.1 ± 10.2	68.2 ± 9.7 *
Weight (kg)	83.0 ± 15.8	85.1 ± 16.1	81.7 ± 15.0 *
Height (cm)	175.4 ± 8.0	175.2 ± 8.2	175.6 ± 7.6
BMI (kg/m2)	27.3 ± 5.0	27.8 ± 5.2	26.5 ± 4.5 *
Education (n, %)	6668		
Primary Education (1st to 7th grade)	221 (3.3)	142 (3.4)	79 (3.3)
Junior Secondary Education (8th and 9th grade)	543 (8.1)	372 (8.8)	171 (7.1)
Secondary Education (10th to 12th grade)	1781 (26.7)	1174 (27.7)	607 (25.1)
Vocational Education and Training (VET)	1742 (26.1)	1144 (27.0)	589 (24.3)
Undergraduate Education	1021 (15.3)	605 (14.3)	416 (17.2)
Postgraduate Education	1360 (20.4)	799 (18.9)	561 (23.2)

Variables	All Female	PD with chronic pain	PD without chronic pain
Total	3930 (37)	2782 (70.8)	1148 (29.2)
Age (mean [SD])	70.5 ± 9.3 #	69.8 ± 9.2	72 ± 9.2 *
Age at onset (mean [SD])	63.4 ± 10.7 #	62.5 ± 10.8	65.7 ± 10.4 *
Age of PD diagnosis (mean [SD])	64 ± 10 #	63.1 ± 10.9	65.1 ± 9.8 *
Age of treatment with levodopa (mean [SD])	65.7 ± 10.2	64.9 ± 10.4	67.8 ± 9.8 *
Weight (kg)	70.2 ± 16.7 #	71.8 ± 17.1	66.6 ± 15.1 *
Height (cm)	161.6 ± 7.5 #	161.7 ± 7.5	161.3 ± 7.6
BMI (kg/m2)	26.2 ± 6.0 #	27.4 ± 6.2	25.5 ± 5.5 *
Education (n, %)	3914		
Primary Education (1st to 7th grade)	100 (2.6)	65 (2.3)	35 (3.1)
Junior Secondary Education (8th and 9th grade)	348 (8.9)	245 (8.9)	103 (9.0)
Secondary Education (10th to 12th grade)	1225 (31.3)	857 (31.0)	368 (32.1)
Vocational Education and Training (VET)	950 (24.3)	703 (25.4)	247 (21.6)
Undergraduate Education	529 (13.5)	371 (13.4)	158 (13.8)
Postgraduate Education	762 (19.5)	527 (19.0)	235 (20.5)

PD, Parkinson's disease; SD, standard deviation; BMI, body mass index; * PD with chronic pain vs PD without chronic pain $p < 0.05$; # female vs male $p < 0.05$

Table 2. Other Forms of chronic pain reported in the APGS cohort

Pain Type	Female (%)	N	Male (%)	N	P
Pain when moving	50.5	1377	52.1	2180	0.67
Pain in joints	49.7	1355	49.4	2067	< 0.05
Pins and needles elsewhere	20	545	19.8	828	0.3
Burning pains in hands/feet	19.7	537	17.1	715	< 0.05
Unidentifiable body ache	18.3	499	15.5	649	< 0.05
Pain from involuntary muscle movements	16.8	458	14.6	611	< 0.05
Pain during 'off' periods	16.6	453	14.3	598	< 0.05
Pain from jerking large muscles	15.5	423	17.1	715	0.3
Pain related to internal organs	11.4	311	7.9	331	< 0.05
Pain from light touch	8.3	226	4.6	192	< 0.05
Pain in mouth	4.1	112	1.9	79	< 0.05
Pain when chewing	4.1	112	2.9	121	< 0.05
Pain when talking	2.1	57	2.1	88	0.67

Table 3. Chronic pain concerning medical comorbidities in the APGS cohort

Clinical variables	PD with chronic pain		PD without chronic pain		P
	N	%	N	%	
Depression	2337	33.2	705	19.6	< 0.05
Sleep Apnoea	1201	17.1	448	12.56	< 0.05
Restless Leg Syndrome	1109	15.8	493	13.7	< 0.05
Essential Tremor	879	12.5	388	10.8	0.05
High Blood Pressure	875	12.4	54	1.5	< 0.05
REM Sleep Behaviour Disorder	833	11.8	270	7.5	< 0.05
Osteoarthitis	680	9.7	26	0.7	< 0.05
Mild Cognitive Impairment	148	2.1	14	0.4	< 0.05
Osteoporosis	248	3.5	15	0.4	< 0.05
Psoriasis	141	2	8	0.2	0.59
Hypothyroidism	130	1.8	6	0.2	< 0.05
Inflammatory Bowel Disease (IBD)	110	1.6	8	0.2	< 0.05
Peptic Ulcer	127	1.8	5	0.1	0.27
Rheumatoid Arthritis	111	1.6	7	0.2	< 0.05

Stroke	112	1.6	10	0.3	0.77

Table 4. Environmental and lifestyle risk factors in the APGS cohort

Lifestyle Factors	PD with chronic pain		PD without chronic pain		P
	N	%	N	%	
Exposed to pesticides/herbicides	2716	38.6	1194	33.2	< 0.05
Heavy metal poisoning	86	1.2	23	0.6	< 0.05
Drinks caffeinated coffee	5335	75.8	2714	75.5	0.72
Drinks tea	4906	69.7	2523	70.2	0.65
Drinks alcohol	4775	22.9	2522	18.4	< 0.05
Ever been a regular smoker (min. 12 months)	179	67.9	53	70.2	< 0.05
Drinks caffeinated soft drinks	1612	2.5	662	1.5	< 0.05

Lifestyle Factors	Female PD with chronic pain		Male PD with chronic pain		P
	N	%	N	%	
Exposed to pesticides/herbicides	826	29.7	1890	44.4	< 0.05

Heavy metal poisoning	31	1.1	55	1.3	0.58
Drinks caffeinated coffee	1994	71.7	3341	78.5	< 0.05
Drinks tea	2048	73.6	2858	67.2	< 0.05
Drinks alcohol	1627	58.5	3148	74	< 0.05
Ever been a regular smoker (min. 12 months)	62	2.2	117	2.8	0.2
Drinks caffeinated soft drinks	495	17.8	1117	26.3	< 0.05

Table 5. Univariate and multivariate logistic regression analyses.

Risk Factor	Univariate Analysis		Multivariate Analysis	
	Unadjusted OR (95% CI)	P	Adjusted OR (95% CI)	P
Female gender	1.39 (1.28, 1.52)	<0.001	1.48 (1.33, 1.63)	<0.001
Age at recruitment, per 5 years	0.87 (0.85, 0.89)	<0.001	0.89 (0.87, 0.92)	<0.001
Body Mass Index (BMI), per kg/m2	1.06 (1.05, 1.07)	<0.001	1.06 (1.04, 1.07)	<0.001
Depression	2.03 (1.85, 2.24)	<0.001	1.70 (1.52, 1.90)	<0.001
REM sleep behaviour disorder	1.65 (1.43, 1.91)	<0.001	1.53 (1.30, 1.81)	<0.001
Pesticide exposure	1.26 (1.16, 1.38)	<0.001	1.34 (1.21, 1.47)	<0.001
Heavy metal poisoning	1.92 (1.21, 3.05)	0.006		
Sleep apnoea	1.44 (1.28, 1.62)	<0.001		
Essential tremor	1.18 (1.04, 1.34)	0.012		
Caffeinated soft drink consumption	1.32 (1.19. 1.49)	<0.001		
Alcohol consumption	0.90 (0.82, 0.98)	0.017		